Research programme: kallikrein inhibitors - BioCryst

Drug Profile

Research programme: kallikrein inhibitors - BioCryst

Latest Information Update: 28 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioCryst Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Bradykinin inhibitors; Kallikrein inhibitors; Tissue factor-factor VIIa complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hereditary angioedema
  • Discontinued Acute coronary syndromes; Cancer; Coronary artery restenosis

Most Recent Events

  • 28 Jan 2018 No recent reports of development identified for preclinical development in Hereditary-angioedema in USA (PO)
  • 20 Dec 2013 Preclinical trials in Hereditary angioedema in USA (PO)
  • 28 Mar 2013 Early research in Hereditary angioedema in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top